Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial.

Kosiborod MN, Windsor SL, Vardeny O, Berger JS, Reynolds HR, Boumakis S, Althouse AD, Solomon SD, Bhatt AS, Peikert A, Luther JF, Leifer ES, Kindzelski AL, Cushman M, Ng Gong M, Kornblith LZ, Khatri P, Kim KS, Baumann Kreuziger L, Javaheri A, Carpio C, Wahid L, Lopez-Sendon Moreno J, Alonso A, Ho MQ, Lopez-Sendon J, Lopes RD, Curtis JL, Kirwan BA, Geraci MW, Neal MD, Hochman JS, ACTIV-4a Investigators

Open source

DOI
10.1016/s2213-8587(24)00218-3
Published
2024 Oct
Container
The lancet. Diabetes & endocrinology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s2213-8587-24-00218-3,
  title = {Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial.},
  author = {Kosiborod MN and Windsor SL and Vardeny O and Berger JS and Reynolds HR and Boumakis S and Althouse AD and Solomon SD and Bhatt AS and Peikert A and Luther JF and Leifer ES and Kindzelski AL and Cushman M and Ng Gong M and Kornblith LZ and Khatri P and Kim KS and Baumann Kreuziger L and Javaheri A and Carpio C and Wahid L and Lopez-Sendon Moreno J and Alonso A and Ho MQ and Lopez-Sendon J and Lopes RD and Curtis JL and Kirwan BA and Geraci MW and Neal MD and Hochman JS and ACTIV-4a Investigators},
  year = {2024},
  journal = {The lancet. Diabetes \& endocrinology},
  doi = {10.1016/s2213-8587(24)00218-3},
  url = {https://doi.org/10.1016/s2213-8587(24)00218-3}
}

RIS

TY  - JOUR
TI  - Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial.
AU  - Kosiborod MN
AU  - Windsor SL
AU  - Vardeny O
AU  - Berger JS
AU  - Reynolds HR
AU  - Boumakis S
AU  - Althouse AD
AU  - Solomon SD
AU  - Bhatt AS
AU  - Peikert A
AU  - Luther JF
AU  - Leifer ES
AU  - Kindzelski AL
AU  - Cushman M
AU  - Ng Gong M
AU  - Kornblith LZ
AU  - Khatri P
AU  - Kim KS
AU  - Baumann Kreuziger L
AU  - Javaheri A
AU  - Carpio C
AU  - Wahid L
AU  - Lopez-Sendon Moreno J
AU  - Alonso A
AU  - Ho MQ
AU  - Lopez-Sendon J
AU  - Lopes RD
AU  - Curtis JL
AU  - Kirwan BA
AU  - Geraci MW
AU  - Neal MD
AU  - Hochman JS
AU  - ACTIV-4a Investigators
PY  - 2024
JO  - The lancet. Diabetes & endocrinology
DO  - 10.1016/s2213-8587(24)00218-3
UR  - https://doi.org/10.1016/s2213-8587(24)00218-3
ER  - 

APA

MN, K., SL, W., O, V., JS, B., HR, R., S, B., AD, A., SD, S., AS, B., A, P., JF, L., ES, L., AL, K., M, C., M, N. G., LZ, K., P, K., KS, K., L, B. K., A, J., C, C., L, W., J, L. M., A, A., MQ, H., J, L., RD, L., JL, C., BA, K., MW, G., MD, N., JS, H., & Investigators, A. (2024). Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial.. The lancet. Diabetes & endocrinology. https://doi.org/10.1016/s2213-8587(24)00218-3

Source records